Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Non-Current Assets (2016 - 2025)

AC Immune has reported Non-Current Assets over the past 11 years, most recently at $72.0 million for Q4 2025.

  • Quarterly Non-Current Assets rose 7.02% to $72.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $72.0 million through Dec 2025, up 7.02% year-over-year, with the annual reading at $72.0 million for FY2025, 7.02% up from the prior year.
  • Non-Current Assets was $72.0 million for Q4 2025 at AC Immune, roughly flat from $72.3 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $65.0 billion in Q4 2023 and troughed at $8.7 million in Q3 2021.
  • The 5-year median for Non-Current Assets is $65.5 million (2024), against an average of $7.4 billion.
  • Year-over-year, Non-Current Assets surged 826772.02% in 2021 and then plummeted 99.91% in 2022.
  • A 5-year view of Non-Current Assets shows it stood at $63.8 billion in 2021, then plummeted by 99.91% to $60.0 million in 2022, then surged by 108162.44% to $65.0 billion in 2023, then tumbled by 99.9% to $67.3 million in 2024, then increased by 7.02% to $72.0 million in 2025.
  • Per Business Quant, the three most recent readings for ACIU's Non-Current Assets are $72.0 million (Q4 2025), $72.3 million (Q3 2025), and $70.6 million (Q2 2025).